These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38216822)

  • 1. Add-on Sacubitril/Valsartan Therapy Induces Left Ventricular Remodeling in Non-responders to Cardiac Resynchronization Therapy to a Similar Extent as in Heart Failure Patients Without Resynchronization.
    Szabó KM; Tóth A; Nagy L; Rácz V; Pólik Z; Hodosi K; Nagy AC; Barta J; Borbély A; Csanádi Z
    Cardiol Ther; 2024 Mar; 13(1):149-161. PubMed ID: 38216822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of sacubitril/valsartan in the management of cardiac resynchronization therapy non-responders: a retrospective analysis.
    Chun KH; Oh J; Yu HT; Lee CJ; Kim TH; Uhm JS; Pak HN; Lee MH; Joung B; Kang SM
    ESC Heart Fail; 2020 Dec; 7(6):4404-4407. PubMed ID: 32918402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up.
    Paolini C; Mugnai G; Dalla Valle C; Volpiana A; Ferraglia A; Frigo AC; Bilato C
    Int J Cardiol Heart Vasc; 2021 Aug; 35():100821. PubMed ID: 34179333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
    Januzzi JL; Prescott MF; Butler J; Felker GM; Maisel AS; McCague K; Camacho A; Piña IL; Rocha RA; Shah AM; Williamson KM; Solomon SD;
    JAMA; 2019 Sep; 322(11):1085-1095. PubMed ID: 31475295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Sacubitril-Valsartan on Ventricular Arrhythmia Burden in Patients With Heart Failure With Reduced Ejection Fraction.
    Medeiros P; Coelho C; Costa-Oliveira C; Rocha S
    Cureus; 2023 Feb; 15(2):e34508. PubMed ID: 36874318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
    Chen F; Tian G; Bai X; Li J; Yuan Z
    Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
    Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
    JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF.
    Guo Y; Ren M; Wang T; Wang Y; Pu T; Li X; Yu L; Wang L; Liu P; Tang L
    Front Cardiovasc Med; 2022; 9():955780. PubMed ID: 36440034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
    Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
    Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of left ventricular reverse remodeling and brain natriuretic peptide level at one year after cardiac resynchronization therapy predicts long-term clinical outcome.
    Roubicek T; Stros J; Kucera P; Nedbal P; Cerny J; Polasek R; Wichterle D
    PLoS One; 2019; 14(7):e0219966. PubMed ID: 31314790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction.
    Nakamura A; Kagaya Y; Saito H; Kanazawa M; Miura M; Kondo M; Sato K; Endo H
    BMC Cardiovasc Disord; 2023 Jan; 23(1):39. PubMed ID: 36681789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
    Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
    Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
    JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacubitril/Valsartan Improves Left Ventricular Ejection Fraction and Reverses Cardiac Remodeling in Taiwanese Patients with Heart Failure and Reduced Ejection Fraction.
    Liu LW; Wu PC; Chiu MY; Tu PF; Fang CC
    Acta Cardiol Sin; 2020 Mar; 36(2):125-132. PubMed ID: 32201463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sacubitril-valsartan on left ventricular remodeling and NT-proBNP in patients with heart failure complicated with hypertension and reduced ejection fraction.
    Xie B; Gao Q; Wang Y; Du J; He Y
    Am J Transl Res; 2024; 16(5):1935-1944. PubMed ID: 38883372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in quality of life with sacubitril/ /valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/Angiotensin) registry.
    Rubio Campal JM; Del Castillo H; Arroyo Rivera B; de Juan Bitriá C; Taibo Urquia M; Sánchez Borque P; Miracle Blanco Á; Bravo Calero L; Martí Sánchez D; Tuñón Fernández J
    Cardiol J; 2021; 28(3):402-410. PubMed ID: 33634846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy.
    Huang HT; Huang JL; Lin PL; Lee YH; Hsu CY; Chung FP; Liao CT; Chiou WR; Lin WY; Liang HW; Chang HY
    ESC Heart Fail; 2022 Dec; 9(6):3825-3835. PubMed ID: 35945811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.
    Ibrahim NE; Piña IL; Camacho A; Bapat D; Felker GM; Maisel AS; Butler J; Prescott MF; Abbas CA; Solomon SD; Januzzi JL;
    Circ Heart Fail; 2020 Nov; 13(11):e007829. PubMed ID: 33016100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac resynchronization therapy in patients with heart failure and moderately reduced ejection fraction: Could it trigger a super-response?
    Tawfik Ghanem M; Allam LE; Samir Ahmed R
    Indian Heart J; 2019; 71(3):229-234. PubMed ID: 31543195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.